See full PI, including Boxed Warning.
©2024 ViiV Healthcare or licensor.
PMUS-DLLWCNT240044 July 2024 Produced in USA.
A Breadth of Data Across Clinical Trials and a Range of People Living With HIV From Real-World Studies3-6*
WHAT CAN THE #1 FASTEST-GROWING SINGLE-TABLET REGIMEN FOR PATIENTS SWITCHING THERAPIES IN 2021, 2022, AND 2023 OFFER YOUR PATIENTS? 3§
§Based on data licensed from IQVIA: Patient Insights (New to Brand) reflecting estimates of real-world activity. All rights reserved. Calculated by % change=[week ending (w/e) 1/8/21–1/29/21] vs [w/e 12/10/21–12/31/21]; [w/e 1/7/22–1/28/22] vs [w/e 12/9/22–12/30/22]; and [w/e 1/6/23–1/27/23] vs [w/e 12/8/23–12/29/23].3
ViiVConnect Savings Card¶
¶Subject to eligibility and program terms and conditions; ViiVConnect programs do not constitute health insurance.
#Subject to patient and prescription eligibility. Up to $6250 per year with no monthly limit for DOVATO. Total savings across eligible ViiV Healthcare medicines not to exceed $7500 per year. Restrictions apply.
Connect With Us
AE=adverse event; CI=confidence interval; CVW=confirmed virologic withdrawal; DTG=dolutegravir; FTC=emtricitabine; TAF=tenofovir alafenamide; TCR=TAF-containing regimen; TDF=tenofovir disoproxil fumarate.
References:
1. The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807. doi:10.1056/NEJMoa1506816
2. Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4(8):e349-e356. doi:10.1016/S2352-3018(17)30066-8
3. Data on file, ViiV Healthcare.
4. Osiyemi O, De Wit S, Ajana F, et al. Efficacy and safety of switching to dolutegravir/lamivudine (DTG/3TC) versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with HIV-1: results through week 144 from the phase 3, noninferiority TANGO randomized trial. Clin Infect Dis. 2022;75(6):975-986. doi:10.1093/cid/ciac036
5. Llibre JM, Brites C, Cheng C-Y, et al. Efficacy and safety of switching to the 2-drug regimen dolutegravir/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with HIV-1: week 48 results from the phase 3, noninferiority SALSA randomized trial. Clin Infect Dis. 2023;76(4):720-729. doi:10.1093/cid/ciac130
6. Rolle C-P, Berhe M, Singh T, et al. Sustained virologic suppression with dolutegravir/lamivudine in a test-and-treat setting through 48 weeks. Open Forum Infect Dis. 2023;10(3):ofad101. doi:10.1093/ofid/ofad101
7. Cahn P, Madero JS, Arribas JR, et al; GEMINI Study Team. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019;393(10167):143-155. doi:10.1016/S0140-6736(18)32462-0
8. De Wit S, Bonnet F, Osiyemi O, et al. Durable efficacy of switching from a 3-/4-drug tenofovir alafenamide (TAF)-based regimen to the 2-drug regimen dolutegravir/lamivudine (DTG/3TC) in the TANGO study through week 196. Presented at: HIV Drug Therapy Glasgow; October 23-26, 2022; Virtual and Glasgow, Scotland. Slides MO41.
9. Cahn P, Madero JS, Arribas JR, et al. Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy-naïve adults with HIV-1 infection. AIDS. 2022;36(1):39-48. doi:10.1097/QAD.0000000000003070
DLLWCNT240011 March 2024